Transgene

Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR

Strasbourg, France, April 17, 2023, 7:30 a.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, presented promising preclinical data on its novel oncolytic virus TG6050, at the American Association for Cancer Research (AACR) Annual Meeting, April 14-19, 2023.
400 Boulevard Gonthier d’Andernach Parc d’Innovation – CS80166 67405 Illkirch-Graffenstaden

+33 (0)3 88 27 91 00